Leber Hereditary Optic Neuropathy Clinical Trial
The Leber Hereditary Optic Neuropathy is a genetic disorder caused by maternal transmission
of mitochondrial DesoxiroboNucleid Acid mutations. It is manifested by a rapidly progressive
blindness, profound, due to atrophic optic nerve. The visual loss is primarily unilateral
bilateralisation taking place in the vast majority of cases in weeks or months. The
neuro-cardio-protective properties of cyclosporine (and its analogs specifically targeting
the anti-apoptotic mechanisms) are particularly promising.
The investigators hypothesis is that cyclosporine may limit apoptosis during the acute phase
of the disease process and would limit the loss of visual acuity and improve the visual
prognosis of these patients.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03475173 -
New Non-invasive Modalities for Assessing Retinal Structure and Function
|
N/A | |
| Active, not recruiting |
NCT03293524 -
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
|
Phase 3 | |
| Completed |
NCT03406104 -
RESCUE and REVERSE Long-term Follow-up
|
Phase 3 | |
| Completed |
NCT03295071 -
REALITY LHON Registry
|
||
| Recruiting |
NCT03011541 -
Stem Cell Ophthalmology Treatment Study II
|
N/A | |
| Completed |
NCT02064569 -
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03153293 -
A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy
|
Phase 2/Phase 3 | |
| Completed |
NCT01267422 -
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
|
N/A |